Systemic lupus erythematosus (SLE) disease itself does not affect the fertility of female patients. SLE patients with active disease requiring treatment with glucocorticoids and immunosuppressants may suffer from menstrual disorders or impaired ovarian function. SLE has an impact on the course and outcome of pregnancy. SLE patients may be at high risk right after pregnancy, which increases pregnancy complications such as eclampsia, premature rupture of membranes, impaired fetal growth, anemia, thrombocytopenia, postpartum hemorrhage, delayed healing of incision and other complications. The fetal mortality rate of antiphospholipid antibody-positive pregnancies is 20-90%, and autoantibodies can cross the placenta and invade the fetus, causing lupus-like syndrome or neonatal lupus, skin damage, congenital atrioventricular block, and organ malformations. Patients who do not need to have children should use contraception. It is for these reasons that for a long time, some doctors believed that SLE patients could not have children. However, studies and observations in recent years have shown that SLE patients with satisfactorily controlled disease and stable function of important organs can conceive and give birth to a child with sound intelligence and physical appearance, provided that the timing of pregnancy is well controlled. It can be said that lupus is no longer a contraindication to childbirth. The prophylactic administration of small doses of hormones during pregnancy is currently advocated for SLE patients to prevent recurrence of the disease during pregnancy to a considerable extent. It is also beneficial to reduce immune damage to the placenta, thus reducing the risk to the fetus as well. Conception should be based on stable disease, generally advocated for more than 1 year, in order to minimize SLE progression and improve pregnancy outcome. Criteria for determining SLE disease activity include the British Lupus Assessment Group (BILAG) scale, the SLE Disease Activity Index (SLEDAI), and others. Easy to understand and grasp by the patient herself are positive urine protein, decreased complement C3 levels, and increased anti-dsDNA antibody levels, changes that suggest disease activity. Eugenics ultrasonography can be used during pregnancy to determine gestational age, to understand embryonic development, and to rule out fetal malformations. Patients with positive antiphospholipid antibodies should be treated until the antiphospholipid antibodies turn negative, and oral aspirin should be taken during pregnancy to prevent thrombosis or miscarriage. Breastfeeding is allowed for mothers taking small doses of prednisone (less than 3 tablets) after delivery, while breastfeeding is not recommended for mothers taking large doses of prednisone or in combination with other medications. Maternal estrogen levels and lactogen levels are high during breastfeeding, and exacerbation of the disease may still occur, and monitoring should still be intensified during this phase. Neonatal lupus is acquired as a result of passively receiving antibodies in maternal blood and manifests itself mainly as fever, skin damage, hepatosplenomegaly, and congenital heart block. Except for the signs and symptoms involving the heart, they are transient and disappear with time, as the maternal antibodies disappear.